<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00219375</url>
  </required_header>
  <id_info>
    <org_study_id>12-601/602/603-0001</org_study_id>
    <nct_id>NCT00219375</nct_id>
  </id_info>
  <brief_title>Study of Sivelestat Sodium Hydrate in Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS) in Japan</brief_title>
  <official_title>Efficacy and Safety of Sivelestat Sodium Hydrate in Acute Lung Injury Associated With Systemic Inflammatory Response Syndrome, Compared With the Conventional Treatment in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the efficacy and safety of sivelestat in patients
      with acute lung injury associated with systemic inflammatory response syndrome. The results
      will be compared to the study with conventional treatment without sivelestat.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilator free days (VFD)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>28-day period survival rate, weaning rate from mechanical ventilation, intensive care unit (ICU) discharge rate, lung injury scores</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">649</enrollment>
  <condition>Acute Lung Injury</condition>
  <condition>Systemic Inflammatory Response Syndrome</condition>
  <arm_group>
    <arm_group_label>E1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm is conducted as a separate study (12-601-0001)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm is conducted as a separate study (12-603-0001).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This arm is conducted as a separate study (12-602-0001)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sivelestat sodium hydrate</intervention_name>
    <description>0.2 mg/kg/hr continuous i.v. infusion - up to 14 days</description>
    <arm_group_label>E1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sivelestat sodium hydrate</intervention_name>
    <description>0.2 mg/kg/hr continuous i.v. infusion - up to 14 days</description>
    <arm_group_label>E2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with systemic inflammatory response syndrome (SIRS)

          2. Patients with acute lung injury (ALI) assessed using the criteria specified by the
             American-European Consensus Conference

          3. Within 72 hours of onset of lung injury

          4. Other inclusion criteria as specified in the protocol

        Exclusion Criteria:

          1. Already administrated Sivelestat before enrollment in the study

          2. Neuromuscular disease that impairs spontaneous ventilation

          3. Severe central nervous system disease

          4. Bone marrow transplant

          5. Lung transplant

          6. Severe chronic liver disease

          7. Neutropenia (neutrophil count: below 1000/mm3)

          8. Other exclusion criteria as specified in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Project Leader, Development Planning</last_name>
    <role>Study Director</role>
    <affiliation>Ono Pharmaceutical Co. Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chubu Region Facility</name>
      <address>
        <city>Chubu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chugoku Region Facility</name>
      <address>
        <city>Chugoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido Region Facility</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokuriku Regional Facility</name>
      <address>
        <city>Hokuriku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanto Regional Facility</name>
      <address>
        <city>Kanto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki Region Facility</name>
      <address>
        <city>Kinki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu Region Facility</name>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shikoku Region Facility</name>
      <address>
        <city>Shikoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku Region Facility</name>
      <address>
        <city>Tohoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>April 21, 2015</last_update_submitted>
  <last_update_submitted_qc>April 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sivelestat sodium hydrate</keyword>
  <keyword>acute lung injury</keyword>
  <keyword>systemic inflammatory response syndrome</keyword>
  <keyword>Elaspol</keyword>
  <keyword>Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sivelestat</mesh_term>
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

